• Research & Development

  PH Therapy INOpulse in Clinical Development Stage

  Posted by Pulmonary Hypertension News Moderator on August 8, 2018 at 7:55 am

  Bellerophon Therapeutics recently provided an update on the clinical development of INOpulse as a treatment for pulmonary arterial hypertension (PAH), as well as for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and interstitial lung disease (PH-ILD).
  

  Click here to read more about this study: Bellerophon Provides Update on Clinical Development of INOpulse for Pulmonary Hypertension

  What are your thoughts on this news?

  replied 5 years, 9 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply